GlassScriptPhysician profile
Jane Irene Lamp
NPI 1659366425
$8,013.77
in general payments reported to CMS, 2019-2025
32 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $1,057 · 2021: $923 · 2022: $1,314 · 2023: $1,428 · 2024: $1,291 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.28 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,662.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,453.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,035.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $632.12 | 2022-2025 | |
| Pfizer INC. | $537.96 | 2020-2025 | |
| Abbvie INC. | $399.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $277.47 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $254.63 | 2022-2025 | Esprit, Freestyle Libre 3 |
| Bausch Health US, LLC | $189.13 | 2020-2023 | Aplenzin, Wellbutrin |
| Biohaven Pharmaceutical Holding Company LTD. | $177.82 | 2022 | |
| Amgen INC. | $168.32 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $142.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $133.61 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $125.07 | 2019-2021 | |
| Amarin Pharma, INC. | $110.79 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $72.61 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.36 | 2019-2020 | |
| Shield Therapeutics INC | $67.40 | 2023 | Accrufer |
| Allergan, INC. | $63.95 | 2019-2020 | |
| Cardiovascular Systems INC. | $62.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.62 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $52.21 | 2020-2021 | |
| Sanofi Pasteur INC. | $45.37 | 2019-2020 | |
| Medtronic, INC. | $34.57 | 2022 | |
| Merck Sharp & Dohme LLC | $32.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2021 | |
| Eisai INC. | $29.38 | 2020-2021 | |
| Seqirus USA INC | $24.45 | 2025 | Flucelvax, Fluad |
| Vivus LLC | $20.56 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.78 | 2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $17.92 | 2019 | |
| Shire North American Group INC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.